Clinical trials of botulinum neurotoxin A: is there a link between funding, pharma, and findings?
- PMID: 33550585
- DOI: 10.1111/dmcn.14836
Clinical trials of botulinum neurotoxin A: is there a link between funding, pharma, and findings?
Comment on
-
Efficacy and safety of abobotulinumtoxinA for upper limb spasticity in children with cerebral palsy: a randomized repeat-treatment study.Dev Med Child Neurol. 2021 May;63(5):592-600. doi: 10.1111/dmcn.14733. Epub 2020 Nov 18. Dev Med Child Neurol. 2021. PMID: 33206382 Free PMC article. Clinical Trial.
References
REFERENCES
-
- Smith R, Gøtzsche PC, Groves T. Should journals stop publishing research funded by the drug industry? BMJ 2014; 348: g171.
-
- Sung KH, Chung CY, Lee KM, et al. Conflict of interest in the assessment of botulinum toxin A injections in patients with cerebral palsy: a systematic review. J Pediatr Orthop 2013; 33: 494-500.
-
- Goldacre B. Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients. London: Fourth Estate, 2012: 430p.
-
- Delgado MR, Tilton A, Carranza-Del Río J, et al. Efficacy and safety of abobotulinumtoxinA for upper-limb spasticity in children with cerebral palsy: a randomized repeat-treatment study. Dev Med Child Neurol 2020 Nov 18. https://doi.org/10.1111/dmcn.14733. [E-pub ahead of print].
-
- Multani I, Manji J, Hastings-Ison T, Khot A, Graham K. Botulinum Toxin in the Management of Children with Cerebral Palsy. Paediatr Drugs 2019; 21: 261-81.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
